Cargando…
Screening for participants in the ISCHEMIA trial: Implications for clinical research
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) found that there was no statistical difference in cardiovascular events with an initial invasive strategy as compared with an initial conservative strategy of guideline-directed medical therap...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389278/ https://www.ncbi.nlm.nih.gov/pubmed/36003207 http://dx.doi.org/10.1017/cts.2022.428 |
_version_ | 1784770408514322432 |
---|---|
author | Rodriguez, Fatima Hochman, Judith S. Xu, Yifan Reynolds, Harmony R. Berger, Jeffrey S. Mavromichalis, Stavroula Newman, Jonathan D. Bangalore, Sripal Maron, David J. |
author_facet | Rodriguez, Fatima Hochman, Judith S. Xu, Yifan Reynolds, Harmony R. Berger, Jeffrey S. Mavromichalis, Stavroula Newman, Jonathan D. Bangalore, Sripal Maron, David J. |
author_sort | Rodriguez, Fatima |
collection | PubMed |
description | The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) found that there was no statistical difference in cardiovascular events with an initial invasive strategy as compared with an initial conservative strategy of guideline-directed medical therapy for patients with moderate to severe ischemia on noninvasive testing. In this study, we describe the reasons that potentially eligible patients who were screened for participation in the ISCHEMIA trial did not advance to enrollment, the step prior to randomization. Of those who preliminarily met clinical inclusion criteria on screening logs submitted during the enrollment period, over half did not participate due to physician or patient refusal, a potentially modifiable barrier. This analysis highlights the importance of physician equipoise when advising patients about participation in randomized controlled trials. |
format | Online Article Text |
id | pubmed-9389278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93892782022-08-23 Screening for participants in the ISCHEMIA trial: Implications for clinical research Rodriguez, Fatima Hochman, Judith S. Xu, Yifan Reynolds, Harmony R. Berger, Jeffrey S. Mavromichalis, Stavroula Newman, Jonathan D. Bangalore, Sripal Maron, David J. J Clin Transl Sci Brief Report The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) found that there was no statistical difference in cardiovascular events with an initial invasive strategy as compared with an initial conservative strategy of guideline-directed medical therapy for patients with moderate to severe ischemia on noninvasive testing. In this study, we describe the reasons that potentially eligible patients who were screened for participation in the ISCHEMIA trial did not advance to enrollment, the step prior to randomization. Of those who preliminarily met clinical inclusion criteria on screening logs submitted during the enrollment period, over half did not participate due to physician or patient refusal, a potentially modifiable barrier. This analysis highlights the importance of physician equipoise when advising patients about participation in randomized controlled trials. Cambridge University Press 2022-07-13 /pmc/articles/PMC9389278/ /pubmed/36003207 http://dx.doi.org/10.1017/cts.2022.428 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Report Rodriguez, Fatima Hochman, Judith S. Xu, Yifan Reynolds, Harmony R. Berger, Jeffrey S. Mavromichalis, Stavroula Newman, Jonathan D. Bangalore, Sripal Maron, David J. Screening for participants in the ISCHEMIA trial: Implications for clinical research |
title | Screening for participants in the ISCHEMIA trial: Implications for clinical research |
title_full | Screening for participants in the ISCHEMIA trial: Implications for clinical research |
title_fullStr | Screening for participants in the ISCHEMIA trial: Implications for clinical research |
title_full_unstemmed | Screening for participants in the ISCHEMIA trial: Implications for clinical research |
title_short | Screening for participants in the ISCHEMIA trial: Implications for clinical research |
title_sort | screening for participants in the ischemia trial: implications for clinical research |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389278/ https://www.ncbi.nlm.nih.gov/pubmed/36003207 http://dx.doi.org/10.1017/cts.2022.428 |
work_keys_str_mv | AT rodriguezfatima screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT hochmanjudiths screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT xuyifan screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT reynoldsharmonyr screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT bergerjeffreys screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT mavromichalisstavroula screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT newmanjonathand screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT bangaloresripal screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch AT marondavidj screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch |